Washington State University

wsu.edu

Total trials

81

Active

25

Phase 3

0

Total enrollment

46,724

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 15 of 15 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Metyrapone And Hydrocortisone1
Dextrose1
insulin1
Mirtazapine1
Hemp-derived cannabinoids1
THC 20mg1
Zonisamide1
Hyperbaric Oxygen Treatment Full1
Hyperbaric Oxygen Treatment Sham1
Hyperbaric Oxygen Treatment Partial Pressure1
Cannabidiol in the form of hemp1
Clopidogrel1
Oxycodone1
Drug cocktail1
Diclofenac1

Next readouts

  • 2025-05-01
  • 2025-08-31
  • 2025-09-15
  • 2025-09-30
  • 2025-12-18
  • 2026-08-31
  • 2026-09-01
  • 2026-11-10
  • 2028-02
  • 2029-03

Top conditions

  • Alcohol Use Disorder6
  • Interaction4
  • Alcohol Use Disorder (AUD)4
  • Hypertension3
  • Family Members3
  • Diabetes3
  • Interaction Drug Food3
  • Opioid Use Disorder3

Frequently asked questions about Washington State University

How many clinical trials does Washington State University have on ClinicalTrials.gov?
Washington State University is listed as the lead sponsor on 81 clinical trials in ClinicalTrials.gov, 25 of which are currently active (recruiting, enrolling, or ongoing).
How many of Washington State University's trials are in Phase 3?
0 of Washington State University's trials are in Phase 3, spread across 15 active drug programs.
What therapeutic areas does Washington State University focus on?
Washington State University's most-studied conditions on ClinicalTrials.gov are Alcohol Use Disorder, Interaction, Alcohol Use Disorder (AUD), Hypertension, Family Members.
When are Washington State University's next clinical trial readouts?
Washington State University has 10 upcoming primary-completion readouts tracked here; the soonest is “Evaluating a Potential Pharmacokinetic Kratom-oxycodone Interaction Concurrent With Clinical Endpoints”, expected around 2025-05-01.